Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Plus Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
NCT03783442Phase 3Completed
- Sponsor
- BeiGene
- Start
- Dec 2018
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeiGene. Started Dec 2018; status: completed.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03783442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03783442.